174 related articles for article (PubMed ID: 36769861)
1. Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study.
Fasolino G; Awada G; Moschetta L; Koulalis JS; Neyns B; Verhelst B; Van Elderen P; Nelis P; de Lichtbuer PC; Cools W; Ten Tusscher M
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769861
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy.
Booth AEC; Hopkins AM; Rowland A; Kichenadasse G; Smith JR; Sorich MJ
Ther Adv Med Oncol; 2020; 12():1758835920944359. PubMed ID: 32821295
[TBL] [Abstract][Full Text] [Related]
3. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
4. New features in MEK retinopathy.
Tyagi P; Santiago C
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):221. PubMed ID: 30255823
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
[TBL] [Abstract][Full Text] [Related]
6. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS.
Méndez-Martínez S; Calvo P; Ruiz-Moreno O; Pardiñas Barón N; Leciñena Bueno J; Gil Ruiz MDR; Pablo L
Retina; 2019 Aug; 39(8):1435-1450. PubMed ID: 30681641
[TBL] [Abstract][Full Text] [Related]
7. A 66-year-old woman with two weeks of distorted vision in the left eye.
Griffin S; McDonald HR; Agarwal A
Retin Cases Brief Rep; 2023 Nov; ():. PubMed ID: 37910636
[TBL] [Abstract][Full Text] [Related]
8. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.
Weber ML; Liang MC; Flaherty KT; Heier JS
JAMA Ophthalmol; 2016 Aug; 134(8):855-62. PubMed ID: 27309887
[TBL] [Abstract][Full Text] [Related]
9. Atypical Presentation of Chorioretinal Folds-Related Maculopathy.
Corvi F; Capuano V; Benatti L; Bandello F; Souied E; Querques G
Optom Vis Sci; 2016 Oct; 93(10):1304-14. PubMed ID: 27560847
[TBL] [Abstract][Full Text] [Related]
10. Serous business: Delineating the broad spectrum of diseases with subretinal fluid in the macula.
van Dijk EHC; Boon CJF
Prog Retin Eye Res; 2021 Sep; 84():100955. PubMed ID: 33716160
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinase inhibitor-associated retinopathy (MEKAR). A clinical case.
Buenasmañanas-Maeso M; Gutiérrez-Montero Ó; Reche-Sainz JA; Badillo Arcones E; Monja-Alarcón N; Toledano-Fernández N
Arch Soc Esp Oftalmol (Engl Ed); 2022 May; 97(5):286-289. PubMed ID: 35526952
[TBL] [Abstract][Full Text] [Related]
12. Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.
van Dijk EHC; Duits DEM; Versluis M; Luyten GPM; Bergen AAB; Kapiteijn EW; de Lange MJ; Boon CJF; van der Velden PA
Medicine (Baltimore); 2016 May; 95(18):e3457. PubMed ID: 27149444
[TBL] [Abstract][Full Text] [Related]
13. Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients.
Jung SM; Valmaggia C; Jörger M; Todorova M
Klin Monbl Augenheilkd; 2021 Apr; 238(4):403-409. PubMed ID: 33930920
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of acute central serous chorioretinopathy on optical coherence tomography - a retrospective study.
Aqil A; Mehmood A; Moin M; Abid K
J Pak Med Assoc; 2020 Oct; 70(10):1834-1837. PubMed ID: 33159763
[TBL] [Abstract][Full Text] [Related]
15. Choroidal vasculature analysis in MEK inhibitor-associated retinopathy.
Cerquaglia A; Lupidi M; Chhablani J; Gujar R; Iaccheri B; Fiore T; Fruttini D; Ramundo A; Vupparaboina KK; Castellani L; Simonetti E; De Carolis L; Tiacci E; Falini B; Cagini C
Eur J Ophthalmol; 2022 Nov; 32(6):3564-3573. PubMed ID: 35195471
[TBL] [Abstract][Full Text] [Related]
16. Ring retinal pigment epithelial window defect of the macula in central serous chorioretinopathy.
Park DW; Schatz H; McDonald HR; Johnson RN
Retina; 1997; 17(3):205-10. PubMed ID: 9196931
[TBL] [Abstract][Full Text] [Related]
17. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
18. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
19. A Case of Non-Resolving MEK Inhibitor-Associated Retinopathy.
Chancellor JR; Kilgore DA; Sallam AB; Allen RC; Uwaydat SH
Case Rep Ophthalmol; 2019; 10(3):334-338. PubMed ID: 31762764
[TBL] [Abstract][Full Text] [Related]
20. Retinal pigment epithelium aperture in acute central serous chorioretinopathy: Another novel possible pathological mechanism.
Lei C; Hua R; Duan J; Zhang M
Eur J Ophthalmol; 2022 Jul; 32(4):NP103-NP108. PubMed ID: 33719657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
